Day: September 3, 2024

  • Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

    NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the acquisition of the royalty rights to “Thank God I Got It” by the renowned artist Desiigner. This acquisition underscores Music Licensing, Inc.’s commitment to diversifying its portfolio with high-quality, revenue-generating assets.

    This strategic purchase adds to a series of recent acquisitions by Music Licensing, Inc., including musical works by iconic artists such as Elton John, Miley Cyrus, Lil Wayne, Rihanna, The Weeknd, Kanye West, Justin Bieber, Mike Posner, Halsey, & many more. These acquisitions align with the company’s strategy to invest in a broad range of musical talents and genres, enhancing its offerings and appeal to a global audience.

    Jake P. Noch, CEO of Music Licensing, Inc., commented on the acquisition, “Securing the rights to ‘Thank God I Got It’ alongside works from other music industry giants significantly strengthens our portfolio and positions us for continued growth. Each of these artists brings a unique sound and fanbase, increasing the potential for robust royalty streams and enriching our company’s asset base.”

    The addition of “Thank God I Got It” to Music Licensing, Inc.’s catalog is part of the company’s broader strategy to leverage high-impact musical works that promise sustainable revenue and cultural relevance. By investing in a wide array of music royalties, the company ensures a dynamic portfolio that meets the diverse tastes of the music listening public and solidifies its market position as a leader in the music industry.

    Listen to “Thank God I Got It” by Desiigner here.

    About Music Licensing, Inc. (OTC: SONG) (ProMusicRights.com)

    Music Licensing, Inc. (OTC: SONG), also known as Pro Music Rights, is a diversified holding company and the fifth public performance rights organization (PRO) formed in the United States. Its licensees include notable companies such as TikTok, iHeart Media, Triller, Napster, 7Digital, Vevo, and many others. Pro Music Rights holds an estimated market share of 7.4% in the United States, representing over 2,500,000 works by notable artists such as A$AP Rocky, Wiz Khalifa, Pharrell, Young Jeezy, Juelz Santana, Lil Yachty, MoneyBagg Yo, Larry June, Trae Pound, Sauce Walka, Trae Tha Truth, Sosamann, Soulja Boy, Lex Luger, Trauma Tone, Lud Foe, SlowBucks, Gunplay, OG Maco, Rich The Kid, Fat Trel, Young Scooter, Nipsey Hussle, Famous Dex, Boosie Badazz, Shy Glizzy, 2 Chainz, Migos, Gucci Mane, Young Dolph, Trinidad James, Chingy, Lil Gnar, 3OhBlack, Curren$y, Fall Out Boy, Money Man, Dej Loaf, Lil Uzi Vert, and countless others, as well as artificial intelligence (A.I.) created music.

    Additionally, Music Licensing, Inc. (OTC: SONG) owns royalty stakes in Listerine “Mouthwash” Antiseptic and musical works by artists such as The Weeknd, Justin Bieber, Kanye West, Elton John, Mike Posner, blackbear, Lil Nas X, Lil Yachty, DaBaby, Stunna 4 Vegas, Miley Cyrus, Lil Wayne, XXXTentacion, Jeremih, Ty Dolla $ign, Eric Bellinger, Ne-Yo, MoneyBagg Yo, Halsey, Desiigner, DaniLeigh, Rihanna, and numerous others.

    Forward-Looking Statements:

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Music Licensing, Inc. & Pro Music Rights, Inc. to accomplish its stated plan of business. Music Licensing, Inc. & Pro Music Rights, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Pro Music Rights, Inc., Music Licensing, Inc., or any other person.

    Non-Legal Advice Disclosure:

    This press release does not constitute legal advice, and readers are advised to seek legal counsel for any legal matters or questions related to the content herein.

    Non-Investment Advice Disclosure:

    This communication is intended solely for informational purposes and does not in any way imply or constitute a recommendation or solicitation for the purchase or sale of any securities, commodities, bonds, options, derivatives, or any other investment products. Any decisions related to investments should be made after thorough research and consultation with a qualified financial advisor or professional. We assume no liability for any actions taken or not taken based on the information provided in this communication.

    Contact: investors@ProMusicRights.com

    SOURCE: Music Licensing, Inc

    GlobeNewswire Distribution ID 9223975

  • ‫شركة Music Licensing, Inc. (OTC: SONG) تعلن استحواذها على حقوق ملكية أغنية “Thank God I Got It” للفنان Desiigner، مما يعزز محفظتها المتنوعة والزاخرة بالنجوم

    نيبلز، فلوريدا،, Sept. 03, 2024 (GLOBE NEWSWIRE) — يَسُر شركة Music Licensing, Inc. (OTC: SONG)، وهي كيان رائد في صناعة الموسيقى، أن تعلن عن استحواذها على حقوق ملكية أغنية “Thank God I Got It” للفنان الشهير Desiigner. ويؤكد هذا الاستحواذ على التزام شركة Music Licensing, Inc. بتنويع محفظتها بأصول عالية الجودة ومُدرّة للإيرادات.

    تُضَاف عملية الشراء الاستراتيجية هذه إلى سلسلة من عمليات الاستحواذ الأخيرة التي قامت بها شركة Music Licensing, Inc. بما في ذلك أعمال موسيقية لفنانين مشهورين مثل Elton John وMiley Cyrus وLil Wayne وRihanna وThe Weeknd وKanye West وJustin Bieber وMike Posner وHalsey وغيرهم الكثير. وتتماشى عمليات الاستحواذ هذه مع استراتيجية الشركة للاستثمار في مجموعة واسعة من المواهب والأنماط الموسيقية، مما يعزز عروضها وجاذبيتها للجمهور العالمي.

    وعلَّق Jake P. Noch، الرئيس التنفيذي لشركة Music Licensing, Inc. على عملية الاستحواذ قائلاً: “إن تأمين حقوق ملكية أغنية “Thank God I Got It” إلى جانب أعمال عمالقة صناعة الموسيقى الآخرين يُقوّي محفظتنا بشكل كبير ويضعنا في مكانة متميزة لمواصلة النمو. يقدم كل من هؤلاء الفنانين صوتًا مميزًا وقاعدة جماهيرية فريدة، مما يزيد من إمكانية تحقيق تدفقات نقدية قوية من العائدات ويثري قاعدة أصول شركتنا.”

    وتأتي إضافة أغنية “Thank God I Got It” إلى مكتبة أغاني شركة Music Licensing, Inc. كجزء من استراتيجية الشركة الأوسع نطاقاً للاستفادة من الأعمال الموسيقية عالية التأثير التي تعد بتحقيق إيرادات مستمرة وأهمية ثقافية. من خلال الاستثمار في مجموعة واسعة من حقوق الملكية الموسيقية، تضمن الشركة وجود حافظة ديناميكية تلبي مختلف الأذواق لجمهور مُستمعي الموسيقى وترسّخ مكانتها في السوق باعتبارها شركة رائدة في صناعة الموسيقى.

    استمع إلى أغنية “Thank God I Got It” لـ Desiigner من هنا.

    عن شركة Music Licensing, Inc. (OTC: SONG) (ProMusicRights.com)

    تشتهر شركة Music Licensing, Inc. (OTC: SONG) أيضًا باسم Pro Music Rights، وهي شركة قابضة متنوعة وتُعد خامس منظمة لحقوق الأداء العام (PRO) يتم تأسيسها في الولايات المتحدة. وتشمل الجهات المُرَخص لها تحت إدارتها شركات بارزة مثل TikTok وiHeart Media وTriller وNapster و7Digital وVevo وغيرها الكثير. تستحوذ شركة Pro Music Rights على حصة سوقية تُقدَّر بـ 7.4% في الولايات المتحدة، حيث تمثل أكثر من 2,500,000 عمل فني لفنانين بارزين مثل A$AP Rocky وWiz Khalifa وPharrell وYoung Jeezy وJuelz Santana وLil Yachty وMoneyBagg Yo وLarry June وTrae Pound وSauce Walka وTrae Tha Truth وSosamann وSoulja Boy وLex Luger وTrauma Tone وLud Foe وSlowBucks وGunplay وOG Maco وRich The Kid وFat Trel وYoung Scooter وNipsey Hussle وFamous Dex وBoosie Badazz وShy Glizzy و2 Chainz وMigos وGucci Mane وYoung Dolph وTrinidad James وChingy وLil Gnar و3OhBlack وCurren$y وFall Out Boy وMoney Man وDej Loaf وLil Uzi Vert، وعدد لا يُحصى من الفنانين الآخرين، بالإضافة إلى الموسيقى التي تم إنشاؤها بواسطة الذكاء الاصطناعي.

    بالإضافة إلى ذلك، تمتلك شركة Music Licensing, Inc. (OTC: SONG) حصص ملكية في Listerine “Mouthwash” Antiseptic وأعمال موسيقية لفنانين مثل The Weeknd وJustin Bieber وKanye West وElton John وMike Posner وblackbear وLil Nas X وLil Yachty وDaBaby وStunna 4 Vegas وMiley Cyrus وLil Wayne وXXXTentacion وJeremih وTy Dolla $ign وEric Bellinger وNe-Yo وMoneyBagg Yo وHalsey وDesiigner وDaniLeigh وRihanna، والعديد من الفنانين الآخرين.

    البيانات التطلعية:

    يحتوي هذا البيان الصحفي على بعض البيانات التطلعية بالمعنى الوارد في نص المادة 27 فقرة (أ) من قانون الأوراق المالية لسنة 1933 بصيغته المعدلة، والمادة 21 فقرة (هـ) من قانون الأوراق المالية لسنة 1934، والتي من المفترض أن تكون مشمولة ضمن قوانين الملاذ الآمن التي تم إصدارها بموجب ذلك. ويتم تحذير المستثمرين من أن جميع البيانات التطلعية تنطوي على مخاطر وعدم يقين، بما في ذلك على سبيل المثال لا الحصر، قدرة شركة Music Licensing, Inc. & Pro Music Rights, Inc على إنجاز خطة عملها المُعلَنة. تعتقد شركة Music Licensing, Inc. & Pro Music Rights, Inc. أن الافتراضات التي تستند إليها البيانات التطلعية الواردة في هذا البيان الصحفي معقولة، وقد تكون أي من الافتراضات غير دقيقة، وبالتالي، لا يمكن ضمان دقة البيانات التطلعية الواردة في هذا البيان الصحفي. وفي ضوء جوانب عدم اليقين الجوهرية الكامنة في البيانات التطلعية الواردة في هذا البيان، لا ينبغي اعتبار إدراج مثل هذه المعلومات بمثابة إقرار من قِبل شركة Pro Music Rights, Inc أو شركة Music Licensing, Inc. أو أي شخص آخر.

    الإفصاح عن المشورة غير القانونية:

    لا يُشكِّل هذا البيان الصحفي مشورة قانونية، ويُنصَح القراء باستشارة مستشار قانوني بشأن أي مسائل أو أسئلة قانونية تتعلق بالمحتوى الوارد بالبيان.

    الإفصاح عن المشورة غير الاستثمارية:

    يهدف هذا البيان إلى أغراض إعلامية فقط، ولا يعني بأي حال من الأحوال أو يُشكِّل توصية أو طلبًا لشراء أو بيع أي أوراق مالية أو سلع أو سندات أو خيارات أو مشتقات أو أي منتجات استثمارية أخرى. يجب اتخاذ أي قرارات تتعلق بالاستثمارات بعد إجراء بحث شامل واستشارة مستشار مالي مؤهل أو متخصص. نحن لا نتحمل أي مسؤولية عن أي إجراءات تم اتخاذها أو لم يتم اتخاذها بناءً على المعلومات الواردة في هذا البيان.

    جهة الاتصال: investors@ProMusicRights.com

    المصدر: Music Licensing, Inc

    GlobeNewswire Distribution ID 9223976

  • Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

    REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies.

    SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic CCM patients.

    REC-994 met its primary endpoint of safety and tolerability, demonstrating a similar profile across placebo and both 200mg and 400mg dosage-arms with regard to the frequency and severity of adverse events after 12 months of treatment. Magnetic resonance imaging-based secondary efficacy endpoints showed a trend towards reduced lesion volume and hemosiderin ring size in patients at the highest dose (400mg) as compared to placebo. Time-dependent improvement in these trends at the 400mg dose was also observed in this signal-finding study. Improvements in either patient or physician-reported outcomes were not yet seen at the 12 month time point. A meeting with the FDA is anticipated as soon as practical to discuss plans for an additional clinical study. Recursion plans to present data from this trial at a forthcoming medical conference and intends to submit these data for publication in a peer reviewed scientific journal.

    “These studies are making significant strides in the development of therapeutics for CCM. The data from this readout is an impressive start and will provide a valuable contribution to the existing CCM literature and strongly supports the need for a future study, with a longer duration and a larger patient cohort,” said Dr. Jan-Karl Burkhardt, MD, Division Head, Cerebrovascular Surgery, University of Pennsylvania and Principal Investigator of the study. Connie Lee, Psy.D., founder and CEO of the Alliance to Cure Cavernous Malformation added: “I speak for the patients who have participated in the trial and those who have been cheering from the sidelines while waiting for news. This promising start is a critical step forward and will bring hope to thousands of families who currently have no options but brain or spinal cord surgery. The Alliance to Cure Cavernous Malformation looks forward to partnering with Recursion as they move to the next stage of the REC-994 program.”

    “We are encouraged by the recent data from our signal-finding Phase 2 study in CCM, where the trial successfully met its primary safety endpoint and became the first investigational therapy to demonstrate safety alongside some promising trends in exploratory efficacy endpoints. These results provide critical insights that will inform our next study design, including exploring study duration, higher doses, and a larger cohort of patients,” said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer of Recursion. “This is the first of several key clinical readouts for the company and represents an early proof-of-platform milestone for our constantly evolving Recursion OS, as we build upon our success in drug discovery with expertise and execution in mid-phase development. We are deeply grateful to the patients and investigators, and we are committed to advancing potential transformational therapies for CCM and beyond.”

    Background on Cerebral Cavernous Malformation (CCM)

    CCM is a neurovascular condition that impacts approximately 360,000 symptomatic individuals in the US and EU5. The disease is often underdiagnosed and potentially affects over 1 million patients worldwide. CCM manifests as vascular malformations of the spinal cord and brain characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. Patients with CCM lesions are at substantial risk for seizures, headaches, progressive neurological deficits, and potentially fatal hemorrhagic stroke. Currently, only non-pharmacologic treatments including microsurgical resection and stereotactic radiosurgery are available options for this high unmet need patient population. However, surgical resection or stereotactic radiosurgery is not always feasible because of location and may not be curative.

    About REC-994

    REC-994 is an orally bioavailable, superoxide scavenger small molecule under development for the treatment of symptomatic CCM. The potential of REC-994 in CCM was demonstrated using the earliest version of what would become the foundational technology underlying the Recursion OS. Subsequently, REC-994 demonstrated preclinical activity in models for CCM and tolerability and suitability for chronic dosing in Phase 1 single ascending dose escalation (SAD) and multiple ascending dose escalation (MAD) trials in healthy volunteers directed and executed by Recursion. Recursion has sought and received Orphan Drug Designation for REC-994 in symptomatic CCM in the US and Europe.

    About the Trial

    Our Phase 2 SYCAMORE clinical trial is a randomized, double-blind, placebo-controlled study of two doses of REC-994 in participants with CCM. The primary endpoint of the study is safety and tolerability. Secondary efficacy endpoints include MRI-based endpoints, clinician and patient reported outcomes, as well as selected biomarkers. This trial was fully enrolled in June 2023 with 62 participants, and 80% of participants who completed 12 months of treatment have entered the long-term extension study. This signal-finding study was not powered to demonstrate statistical significance.

    About Recursion

    Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

    Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

    Media Contact
    Media@Recursion.com

    Investor Contact
    Investor@Recursion.com

    Forward-Looking Statements

    This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s anticipated meeting with the FDA; Recursion’s plans to present SYCAMORE trial data at a medical conference and submit the data for publication; the clinical relevance of the SYCAMORE trial data and obtaining additional confirmatory data; promising trends in REC-994 efficacy endpoints; advancing potential transformational therapies for CCM and beyond; subsequent REC-994 studies and their results and advancing Recursion’s REC-994 program further; the size of the potential CCM patient population; Recursion OS and other technologies potential and advancement of the future of medicine; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

    GlobeNewswire Distribution ID 9223929

  • ‫”سيام – شركة المنتجات الخرسانية والركام” و”سامسونج إي آند ايه” توقعان مذكرة تفاهم

    لتعزيز تكنولوجيا الطباعة ثلاثية الأبعاد والمواد الأسمنتية الخاصة في السوق العالمية

     

    بانكوك، تايلاند – 2 سبتمبر 2024 – بالنيابة عن شركة المنتجات الخرسانية والركام (CPAC)، وهي شركة أسمنت ومواد بناء تابعة لمجموعة سيام للأسمنت (SCG)، وقع السيد/ ثاماساك سيثودوم، رئيس مجلس الإدارة والرئيس التنفيذي لشركة سيام (الثاني من اليسار) والسيد/ سوراتشاي نيملاور، رئيس شركة سيام للأسمنت والحلول الخضراء (الأول من اليسار)، مذكرة تفاهم مع السيد/ هونغ نامكونغ، رئيس مجلس الإدارة والرئيس التنفيذي لشركة سامسونج إي آند ايه المحدودة (الثاني من اليمين) والسيد/ دونغ هيون كيم، نائب الرئيس التنفيذي لقسم تكنولوجيا الهندسة لشركة سامسونج إي آند ايه المحدودة (الأول من اليمين) للتعاون في مجال الطباعة ثلاثية الأبعاد وفرص تسويق المواد الأسمنتية الخاصة، والتي تجمع بين الخبرة الدولية لشركة سامسونج إي آند ايه ومقرها كوريا الجنوبية في حلول البناء الشاملة وسجل التميز لشركة المنتجات الخرسانية والركام الذي يمتد لأكثر من 100 عام في منتجات الأسمنت والخرسانة والتكنولوجيا معًا لرفع مستوى صناعة البناء التايلاندية لتتناسب مع المستوى العالمي، بالطابق الحادي والعشرين، بالمقر الرئيسي لشركة سيام، في بانكوك، تايلاند، في 21 أغسطس 2024.

    وتظهر مذكرة التفاهم هذه أن الشركتين تشتركان في نفس الرؤية في قيادة مستقبل البناء المستدام في العالم من خلال الابتكار والتكنولوجيا الجديدة، وخاصة تقنية الطباعة ثلاثية الأبعاد التي توفر كفاءة أعلى في الإنتاج وتقلل الأخطاء من خلال تمكين عملية الأتمتة من ملف رقمي تم إنشاؤه بواسطة برنامج كمبيوتر. يمكن أن يساعد هذا أيضًا في حل مشكلة نقص القوى العاملة الماهرة، وتقصير فترة البناء، وتقليل نفايات البناء وتكاليف البناء مقارنة بالبناء التقليدي. وتتضمن مذكرة التفاهم أيضًا التعاون البحثي في ​​علوم المواد والآلات والمعدات بالإضافة إلى تبادل المعرفة حول البناء بالطباعة ثلاثية الأبعاد والمواد الأسمنتية الخاصة. تخطط شركة سامسونج إي آند ايه لاستخدام 350 طنًا من ​​مونة الطباعة ثلاثية الأبعاد الحاصل على براءة اختراع، والذي يمكنه تطوير هياكل معقدة التصميم ذات قوة عالية للغاية، لبناء مبنى في المملكة العربية السعودية. بالنسبة لهذا المشروع، ستقدم شركة المنتجات الخرسانية والركام الدعم الاستشاري التكنولوجي حول الطباعة ثلاثية الأبعاد، والاستشارات الهندسية، ودعم تقييم المشروع للخدمات المهنية في التصميم المعماري وغيرها من الاعتبارات الجمالية بالإضافه إلى المونة اللازمه للطباعة ثلاثية الأبعاد.

    من اليسار إلى اليمين

    1. السيد/ سوراتشاي نيملاور رئيس شركة سيام للأسمنت والحلول الخضراء
    2. السيد/ ثاماساك سيثودوم الرئيس والرئيس التنفيذي لمجموعة سيام للأسمنت
    3. السيد/ هونغ نامكونغ الرئيس والرئيس التنفيذي لشركة سامسونج إي آند ايه المحدودة
    4. السيد/ دونج هيون كيم نائب الرئيس التنفيذي لقسم تكنولوجيا الهندسة بشركة سامسونج إي آند ايه المحدودة

     

  • “SCG – CPAC” and “Samsung E&A” sign MOU to bolster 3D printing technology and special cementitious materials in global market

    BANGKOK, THAILAND – Media OutReach Newswire – 2 September 2024 – On behalf of CPAC, a cement and building materials company under Siam Cement Group (SCG), Mr. Thammasak Sethaudom, President & CEO of SCG (second from the left), and Mr. Surachai Nimlaor, President of SCG Cement and Green Solution Business (first from the left), signed the Memorandum of Understanding (MoU) with Mr. Hong Namkoong, President and CEO of SAMSUNG E&A Co., Ltd. (second from the right) and Mr. Dong Hyun Kim, Executive Vice President Engineering Technology Division of SAMSUNG E&A Co., Ltd. (first from the right) for the collaboration on 3D Printing and special cementitious materials commercialization opportunities, which brings South Korea-based SAMSUNG E&A company’s international expertise in end-to-end construction solutions and CPAC’s over 100 years record of excellence in cement and concrete products and technology together to elevate the standard of the Thai construction industry to match the global level, on the 21st Floor, SCG Headquarter Bangkok Thailand, on August 21, 2024.

    This MOU shows that both companies have shared the same vision in driving the world’s sustainable construction future with new innovation and technology, particularly 3D printing technology that provides higher efficiency in production and minimizes errors by enabling the automation process from digital file generated by a computer software. This can also help to solve the skilled workforce shortage, shorten the construction period, and reduce construction waste and construction costs compared to traditional construction. The MOU also includes the research collaboration on materials science, machinery and equipment as well as the knowledge sharing about 3D printing construction and special cementitious materials. SAMSUNG E&A plans to use 350 tons of its patented 3D printing mortar, which can develop complex-designed structures with ultra-high strength, for the construction of a building in Saudi Arabia. For this project, CPAC will provide technology consultation support about 3D printing, Engineering Consultation, and Project Evaluation Support to professional services in architectural design and other aesthetic considerations.

    From left to right
    1. Mr. Surachai Nimlaor President of SCG Cement and Green Solution Business
    2. Mr. Thammasak Sethaudom President & CEO of SCG (Siam Cement Group)
    3.Mr. Hong Namkoong President and CEO of SAMSUNG E&A Co., Ltd.
    4.Mr. Dong Hyun Kim Executive Vice President Engineering Technology Division of SAMSUNG E&A Co., Ltd.

  • “SCG – CPAC” and “Samsung E&A” sign MOU to bolster 3D printing technology and special cementitious materials in global market

    BANGKOK, THAILAND – Media OutReach Newswire – 2 September 2024 – On behalf of CPAC, a cement and building materials company under Siam Cement Group (SCG), Mr. Thammasak Sethaudom, President & CEO of SCG (second from the left), and Mr. Surachai Nimlaor, President of SCG Cement and Green Solution Business (first from the left), signed the Memorandum of Understanding (MoU) with Mr. Hong Namkoong, President and CEO of SAMSUNG E&A Co., Ltd. (second from the right) and Mr. Dong Hyun Kim, Executive Vice President Engineering Technology Division of SAMSUNG E&A Co., Ltd. (first from the right) for the collaboration on 3D Printing and special cementitious materials commercialization opportunities, which brings South Korea-based SAMSUNG E&A company’s international expertise in end-to-end construction solutions and CPAC’s over 100 years record of excellence in cement and concrete products and technology together to elevate the standard of the Thai construction industry to match the global level, on the 21st Floor, SCG Headquarter Bangkok Thailand, on August 21, 2024.

    This MOU shows that both companies have shared the same vision in driving the world’s sustainable construction future with new innovation and technology, particularly 3D printing technology that provides higher efficiency in production and minimizes errors by enabling the automation process from digital file generated by a computer software. This can also help to solve the skilled workforce shortage, shorten the construction period, and reduce construction waste and construction costs compared to traditional construction. The MOU also includes the research collaboration on materials science, machinery and equipment as well as the knowledge sharing about 3D printing construction and special cementitious materials. SAMSUNG E&A plans to use 350 tons of its patented 3D printing mortar, which can develop complex-designed structures with ultra-high strength, for the construction of a building in Saudi Arabia. For this project, CPAC will provide technology consultation support about 3D printing, Engineering Consultation, and Project Evaluation Support to professional services in architectural design and other aesthetic considerations.

    From left to right
    1. Mr. Surachai Nimlaor President of SCG Cement and Green Solution Business
    2. Mr. Thammasak Sethaudom President & CEO of SCG (Siam Cement Group)
    3.Mr. Hong Namkoong President and CEO of SAMSUNG E&A Co., Ltd.
    4.Mr. Dong Hyun Kim Executive Vice President Engineering Technology Division of SAMSUNG E&A Co., Ltd.

  • Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device

    Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device

    FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end of 2024

    U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised

    Nyxoah – NASDAQ Closing Bell Ceremony 29 août 2024

    Mont-Saint-Guibert, Belgium – September 2, 2024 10:05pm CET / 4:05PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), rang the Nasdaq Closing Bell on August 29, 2024 to recognize the Company’s recent progress and highlight upcoming milestones on its path to the U.S. market launch of its innovative patient-centric Genio® hypoglossal nerve stimulation technology for OSA, a prevalent and severe sleep-related breathing disorder associated with increased mortality risk and cardiovascular comorbidities.

    “We are honored to ring the Closing Bell and to celebrate our recent clinical and regulatory achievements in the U.S. We look forward with excitement to the upcoming U.S. launch of our lead product, Genio,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “The U.S. is the largest healthcare market globally and therefore of strategic importance for us. With robust clinical evidence from our pivotal DREAM study, solid funding in place and our strengthened US commercial team, we feel well positioned to enter the US market. We have submitted the final module of our PMA submission to the FDA and are on track for U.S. approval by the end of 2024. If approved, Genio could become available in the U.S. as early as the beginning of 2025.”

    Olivier Taelman, CEO of Nyxoah – NASDAQ Closing Bell Ceremony 29 august 2024

    Recent Highlights and Upcoming Milestones of Nyxoah’s U.S. Commercialization Strategy

    • Announcement of positive data from the pivotal U.S. study, DREAM, regarding Nyxoah’s Genio® system, an innovative hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA) in spring 2024.
    • Final module submitted in the modular PMA submission, initiating FDA interactive review.
    • Building a U.S. commercial organization, headed by Scott Holstine as the new Chief Commercial Officer along with key sales, marketing and market access leaders.
    • The U.S. market launch of Genio® is fully funded following the successful raising of over €85 million in growth capital through a €48.5 million equity offering and a €37.5 million loan facility agreement with the European Investment Bank (EIB).
    • FDA approval expected approval by US Food and Drug Administration by the end of 2024.
    • U.S. market launch of Genio® planned for the beginning of 2025.

    To view the broadcast of the Nasdaq Closing Bell ceremony, please visit: https://www.nasdaq.com/news-and-insights/nasdaq-stock-market-bell-ceremonies

    About Nyxoah

    Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

    Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

    For more information, please see the Company’s annual report for the financial year 2023 and visit http://www.nyxoah.com/.

    Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

    Forward-looking statements

    Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the entry into of the loan facility agreement and the synthetic warrant agreement with the EIB; the use of proceeds from the loan facility agreement; the Genio® system and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; reporting data from Nyxoah’s DREAM U.S. pivotal trial; filing for FDA approval; and entrance to the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

    Contacts:

    Nyxoah
    Loïc Moreau, Chief Financial Officer
    IR@nyxoah.com

    For Media
    Belgium/France
    Backstage Communication – Gunther De Backer
    gunther@backstagecom.be

    International/Germany
    MC Services – Anne Hennecke
    nyxoah@mc-services.eu

    Attachment

    GlobeNewswire Distribution ID 1000989628

  • UN Special Coordinator for Middle East Peace: Scale of Destruction in Gaza Strip Is Immense

    United Nations Special Coordinator for the Middle East Peace Process Tor Wennesland said that the scale of destruction in the Gaza Strip is immense, the humanitarian needs are colossal and soaring, and civilians continue to bear the brunt of this conflict.

    “During my visit, I met with the heads of UN agencies and our dedicated staff working tirelessly in extremely challenging conditions. Their commitment and bravery in providing critical support to those in need is truly commendable,” Wennesland said in a statement.

    “I also had the opportunity to visit a Polio vaccination center. Its reemergence represents yet another threat to the children in the Gaza Strip,” he added.

    He stressed that every day that passes puts more lives in danger, reiterating his call for an immediate humanitarian ceasefire.

    The Israeli occupation has been waging a comprehensive war of genocide on the Gaza Strip for more than ten months, resulting in tens of thousands of martyrs, injured, and missing, most of whom are children and wom
    en. Additionally, around two million people have been displaced amidst the massive destruction of health and educational infrastructure, as well as the halt of food, water, medicine, and fuel supplies, leading to a famine that has claimed the lives of dozens of children

    Source: Qatar News Agency

Back to top button